Floatz logo

FALLYPRIDE

Neoadjuvant Immunotherapy

Shanghai Pulmonary Hospital, Shanghai, ChinaSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Neoadjuvant Immunotherapy cohort.

Asset / SponsorPhaseRating
Iparomlimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Tisleizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Catequentinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Shanghai Pulmonary Hospital, Shanghai, China
D

Same molecule, other indications

FALLYPRIDE is also rated in:

Alzheimer DementiaDormant
BB
Indicative ·
67 / 100
View asset →
Essential TremorDormant
BB
Indicative ·
64 / 100
View asset →
Breast CancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →